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Gene amplification of Sox2 at 3q26.33 is a common
event in squamous cell carcinomas (SCCs) of the
lung and esophagus, as well as several other can-
cers. Here, we show that the expression of LSD1/
KDM1 histone demethylase is significantly elevated
in Sox2-expressing lung SCCs. LSD1-specific inhib-
itors selectively impair the growth of Sox2-express-
ing lung SCCs, but not that of Sox2-negative cells.
Sox2 expression is associated with sensitivity to
LSD1 inhibition in lung, breast, ovarian, and other
carcinoma cells. Inactivation of LSD1 reduces Sox2
expression, promotes G1 cell-cycle arrest, and in-
duces genes for differentiation by selectively modu-
lating the methylation states of histone H3 at lysines
4 (H3K4) and 9 (H3K9). Reduction of Sox2 further
suppresses Sox2-dependent lineage-survival onco-
genic potential, elevates trimethylation of histone
H3 at lysine 27 (H3K27) and enhances growth arrest
and cellular differentiation. Our studies suggest that
LSD1 serves as a selective epigenetic target for ther-
apy in Sox2-expressing cancers.
INTRODUCTION
Lung cancer is the most frequent cause of cancer death world-
wide (Jemal et al., 2009; Jones et al., 2006). Squamous cell
carcinoma (SCC) of the lung is a major form of frequent and
aggressive lung cancer (Jones et al., 2006). Recent studies
have shown that the gene amplification of Sox2, which encodes
a high-mobility group domain-containing transcription factor, is
the most frequent and common event in SCCs of the lung,
esophagus, and oral cavity at 3q26.33 (Bass et al., 2009; Husse-
net et al., 2010; Maier et al., 2011). It is also amplified in a fraction
of small cell lung carcinomas (Rudin et al., 2012) and glioblas-Ctoma multiforme (GBM) (Alonso et al., 2011). Sox2 is a master
regulator of pluripotent embryonic stem cells (ESCs) and adult
neural stem cells (Episkopou, 2005; Okita and Yamanaka,
2006). It reprograms somatic cells into induced pluripotent
stem cells (iPSCs) with Oct4, Klf4, and c-Myc, or with Oct4, Lin
28, and Nanog (Takahashi et al., 2007; Yu et al., 2007). Sox2
also plays an essential role in themorphogenesis and homeosta-
sis of esophageal, tracheobronchial, and bronchiolar epithelia
(Que et al., 2007). Sox2 acts as a lineage-survival oncogene for
the expression of pluripotent stem cell (PSC) signatures and
the lineage-specific genes in lung SCCs (Bass et al., 2009).
Ectopic expression of Sox2 causes the oncogenic transforma-
tion of normal tracheobronchial epithelial cells (Bass et al.,
2009). Sox2 is frequently expressed in other types of poorly
differentiated and aggressive human cancers (Ben-Porath
et al., 2008). In lung adenocarcinomas, Sox2 expression is asso-
ciated with poor prognosis (Sholl et al., 2010). In stem cell-like
ovarian cancer cells, Sox2 is also coexpressed with Oct4 and
Lin28 (Peng et al., 2010; Zhong et al., 2010). In breast carci-
nomas, expression of Sox2 is required for mammosphere forma-
tion as part of its stem cell-like properties (Leis et al., 2012). In co-
lon cancer, Sox2 expression correlates with lymph-node and
distant metastases (Neumann et al., 2011). In these cancers,
Sox2 appears to confer certain progenitor/stem cell properties
to carcinoma cells to allow them to differentiate.
Histone methylation is a major covalent modification of his-
tones that provides the structural and functional characteristics
of chromatin to epigenetically define gene-expression patterns
in a cell (Klose and Zhang, 2007; Shi, 2007). LSD1 (also known
as KDM1, AOF2, or BHC110) is a highly conserved flavin adenine
dinucleotide (FAD)-dependent, lysine-specific demethylase that
was initially found to specifically remove mono- and dimethyl
groups from methylated histone H3 at lysine 4 (H3K4) to sup-
press gene expression. In prostate cancer cells, it also demethy-
lates the repressive mono- and dimethylated lysine 9 (H3K9)
in an androgen-receptor-dependent manner (Metzger et al.,
2005; Shi et al., 2004). Recent studies indicated that LSD1 is
an essential epigenetic regulator of pluripotency in ESCs (Adamoell Reports 5, 445–457, October 31, 2013 ª2013 The Authors 445
et al., 2011;Whyte et al., 2012).We previously showed that LSD1
levels are significantly elevated in cells derived from pluripotent
germ cell tumors such as teratocarcinoma, embryonic carci-
noma, and seminoma cells (Wang et al., 2011). Our LSD1 inhib-
itors selectively inhibited the growth of ESCs and pluripotent
germ tumor cells (Wang et al., 2011). LSD1 is also essential for
maintaining the oncogenic potential of MLL-AF9 leukemia stem
cells and acute myeloid leukemia (Harris et al., 2012; Schenk
et al., 2012). However, the critical downstream targets of LSD1
in ESCs and cancer cells remain unclear. Here, we report that
Sox2 serves as the critical target of LSD1 in a wide variety of
human carcinoma cells.
RESULTS
LSD1 Expression Is Elevated in Human Lung SCCs that
Overexpress Sox2
Our previous studies indicated that germ tumor cells such as
teratocarcinoma and embryonic carcinoma cells expressed
elevated levels of LSD1. They were also highly sensitive to our
LSD1-specific inhibitors that noncovalently interact with LSD1
(Wang et al., 2011). Given that these cells usually express the
PSC proteins Oct4, Sox2, and Lin28, which are also expressed
in other human cancers (Leis et al., 2012; Peng et al., 2010;
Zhong et al., 2010), we examined LSD1 in various human cancer
tissues that also coexpress some of the PSC markers (only dei-
dentified samples were used, which were acquired with the
approval of the Ethics Committee of the First Affiliated Hospital,
Shihezi University School of Medicine). In 13 independent cases
of human lung SCC, we observed highly elevated levels of Sox2
and LSD1 in five poorly differentiated cases, moderate Sox2 and
LSD1 increases in seven moderately differentiated cancer
cases, and low LSD1 expression in a single Sox2-negative and
moderately differentiated cancer (Figure 1A; Figure S1A avail-
able online; Table S1). Statistical analysis revealed a significant
correlation between Sox2 and LSD1 expression (Pearson’s
correlations: R2 = 0.4372 and p = 0.014). In contrast, Sox2
expression was low or nondetectable in all 17 cases of lung
adenocarcinoma carcinomas. In the lung adenocarcinoma
samples, only two cases of poorly differentiated cancers had
moderately increased levels of LSD1, and LSD1 was low in the
remaining 15 moderately differentiated cancers. As a control,
the surrounding normal lung tissues expressed undetectable
levels of LSD1 and Sox2 proteins (Figure 1A).
Our finding that the levels of LSD1 are significantly elevated in
Sox2-expressing SCCs is consistent with previously reported
studies. For example, in a search of publicly reported tumor
microarray data from Oncomine (http://www.oncome.org), we
found that in 21 SCC cases reported by Bhattacharjee et al.
(2001), Sox2 was overexpressed in 18 cases, whereas LSD1
was co-overexpressed in 16 cases. In another six small cell
lung carcinoma cases with elevated LSD1, Sox2 was also over-
expressed in four of them. In 17 cases of esophagus carcinomas
(Hu et al., 2010) with high LSD1 levels, Sox2 was overexpressed
in 14 cases. The overexpression of Sox2 and LSD1 was also
found in other cancers. For example, in 19 cases of large cell
lung carcinomas (Hou et al., 2010), 16 cases overexpressed
LSD1 and 15 overexpressed Sox2. In a study of cervical SCCs446 Cell Reports 5, 445–457, October 31, 2013 ª2013 The Authors(Scotto et al., 2008), Sox2 was overexpressed in 50% of 84
cases and LSD1 was coelevated in 48% of all cases. In 122
cases of ductal breast carcinomas (Sorlie et al., 2003),
Sox2 was overexpressed in 52% of them and LSD1 was co-
overexpressed with Sox2 in 49% of all cases. In a single undif-
ferentiated breast carcinoma case, both Sox2 and LSD1 were
overexpressed. Our studies suggest that there is a significant
correlation between Sox2 and LSD1 expression in a wide array
of human cancers.
Lung SCC Cells that Contain Amplified Sox2 Gene or
Other Lung Carcinoma Cells that Express Sox2 Are
Particularly Sensitive to LSD1 Inactivation
Our observation that LSD1 levels are elevated in Sox2-express-
ing lung SCCs prompted us to investigate the functional relation-
ship between Sox2 and LSD1 in lung carcinomas. For this
purpose, we used human SCC NCI-H520 cells that contain the
Sox2 gene amplification at 3q26.33, and human lung adenocar-
cinoma NCI-H1437 cells that do not express Sox2 (Bass et al.,
2009; Figure 1B). H520 and H1437 cells were treated with
LSD1 inhibitors for 24–30 hr, and cell growth was analyzed.
We found that the LSD1 inhibitor CBB1007 selectively and spe-
cifically inhibited the growth of H520 cells, but had no detectable
effects on H1437 cells (Figures 1C and 1D).
We wondered whether the elevated expression of Sox2 is
responsible for such sensitivity to LSD1 inhibitors in lung
cancer cells. To identify additional Sox2 or other PSC-specific
gene-expression signatures in carcinoma cells, we searched
the microarray mRNA data of the Cancer Genome Anatomy
Project database (http://cgap.nci.nih.gov/Microarray/GeneList)
in 60 cancer cell lines collected by the National Cancer
Institute. Using this approach, we found that approximately
one-third of these cancer cells express Sox2 or other PSC
proteins. Treatment of A549, a Sox2-expressing human lung
adenocarcinoma cell derived from adenocarcinomic alveolar
basal epithelial cells, and H1299, a Sox2-negative human
non-small cell lung carcinoma cell (Figure 1B), with LSD1 inhib-
itors revealed that A549 cells are highly sensitive to LSD1
inhibitors, whereas H1299 cells are not (Figures 1C and 1D).
We also ablated the expression of LSD1 using specific
siRNAs in H520, H1437, A549, and H1299 cells, and these
studies showed that ablation of LSD1 phenocopied the selec-
tive growth-inhibitory effects of LSD1 inhibitors on H520 and
A549 cells, but not on H1437 and H1299 cells (Figures 1C
and 1D). Our results indicate that lung carcinoma cells that
express Sox2 are particularly sensitive to LSD1 inactivation,
whereas Sox2-negative cells are not. In addition, both Sox2-
expressing H520 and A549 cells appeared to express higher
levels of LSD1 (Figure 1B).
Breast and Ovarian Carcinoma Cells Can Be
Distinguished by their Sensitivity to LSD1 Inhibition
Although LSD1 inhibitors specifically target lung carcinoma cells
that overexpress Sox2, it remains unclear whether lung carci-
noma cells are uniquely sensitive to LSD1 inhibition. A search
of the Cancer Genome Anatomy Project database and pub-
lished reports revealed that several breast and ovarian carci-
noma cells may also express the key PSC proteins Oct4,
Figure 1. LSD1 and Sox2 Expression in Lung SCCs and Lung Carcinoma Cells that Express Sox2 Are Selectively Sensitive to LSD1
Inactivation
(A) LSD1 and Sox2 expression in lung SCCs. One example of serial tissue sections from clinical lung SCC patients (n = 13) immunostained with Sox2 or LSD1
antibodies. LSD1 and Sox2 were strongly stained in pathological tissues (right), but weakly stained or nondetectable in normal lung tissue (left) surrounding the
pathological areas. Scale bar: 100 mm. Lower panels represent magnified images (43 of upper panels; total magnification: 4003). See also Figures S1A and S1B.
(B) Sox2 and LSD1 expression in human lung SCC NCI-H520, lung adenocarcinoma A549, and lung carcinoma NCI-H1437 and H1299 cells. CUL1 and histone
H3: loading control.
(C) LSD1 inactivation specifically inhibited the growth of H520 and A549 cells, but not that of H1437 or H1299 cells. Actively growing lung cancer cells were treated
with 50 mM LSD1 inhibitor CBB1007 for 30 hr or were transfected with 50 nM control luciferase (Luc) or LSD1 siRNAs for 60 hr. Cell growth was examined by
microscopy.
(D) Percent viability of cells treated with LSD1 inhibitors or siRNAs compared with control cells, as determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) assay. Data are presented asmean ±SD. The statistical differences between inhibitor-treated and control groups were analyzed by one-
way ANOVA. Scale bar: 100 mm. **p < 0.01.
See also Figures S2, S7, and Table S1.Sox2, Lin28, Nanog, and Sall4 either alone or in combination
(Leis et al., 2012; Peng et al., 2010; Zhong et al., 2010). We
therefore examined a panel of ovarian, breast, and other carci-
noma cells for their response to LSD1 inhibition (Table S2).
Although the growth of some cells was not inhibited by LSD1
inhibitors such as human ovarian carcinoma cells OVCAR8,
Hs38.T, and ES-2, and breast carcinoma cells MDA-MB-231,
BT549, and SK-BR-3, several of them were highly sensitive to
LSD1 inhibitors such as ovarian carcinoma cells OVCAR3,
A2780, SKOV-3, and IGROV-1; ovarian teratocarcinoma PA-1
cells; and breast carcinoma cells MDA-MB-468, T47D, andCMCF-7 (Figures 2A, 2B, S1C, S1D, and S2A–S2C). We
confirmed the selective effects of LSD1 inhibitors by ablation
of LSD1 using LSD1 siRNAs (Figures 2A and 2C). Analysis of
the cell-cycle effects by fluorescence-activated cell sorting
(FACS) revealed that loss of LSD1 induced significant G1 cell-
cycle arrest in cancer cells that are sensitive to LSD1 inhibition,
such as A549, T47D, and IGROV1, which was associated with
decreased expression of the cell-cycle regulatory proteins c-
Myc and various cyclins, whereas such an arrest was not
observed in cancer cells that are not sensitive to LSD1 inhibi-
tors, such as H1437 (Figures 2E, 3G, and S3A).ell Reports 5, 445–457, October 31, 2013 ª2013 The Authors 447
Figure 2. LSD1-Inactivation-Induced Growth Inhibition Is AssociatedOnly with Sox2 Expression in Lung, Breast, Ovarian, andOther Types of
Carcinoma Cells
(A) Effects of LSD1 inhibitor CBB1007 and siRNAs on the growth of ovarian carcinoma OVCAR-8, OVCAR-3, and A2780 cells, and breast carcinoma MDA-MB-
231, MDA-MB-468, and T47D cells. See also Figures S1C, S1D, S2A–S2C, S2E, S2F, and S7B–S7D.
(B and C) Quantitative analyses of the sensitivity of a panel of breast, ovarian, and other human carcinoma cells to LSD1 inhibitors (B) and LSD1 siRNA-mediated
ablation (C). The statistical differences between inhibitor-treated and control groups were analyzed by one-way ANOVA. *p < 0.05, **p < 0.01.
(D) Analysis of the expression of Oct4, Sox2, Nanog, Lin28, Sall4, and other proteins in lung, breast, ovarian, teratocarcinoma, embryonic carcinoma, and other
carcinoma cells as indicated. Cells that are sensitive to LSD1 inactivation are indicated by *. Among PSC proteins, only the expression of Sox2 correlates with the
growth-inhibitory effects of LSD1 inactivation. See also Table S2 for summary.
(E) Ablation of LSD1 by siRNAs induces G1 cell-cycle arrest in Sox2-expressing A549, T47D, and IGROV1 cells, but not in Sox2-negative H1437 carcinoma cells.
The distributions of the cell-cycle population were as follows:
A549 cells, Luc siRNA: G0/G1: 54.64%, S: 28.42%, G2/M: 16.94%; and A549, LSD1 siRNA: G0/G1: 74.81%, S: 24.55%, G2/M: 0.65%.
IGROV1 cells, Luc siRNA: G0/G1: 55.48%, S: 27.48%, G2/M: 17.04%; and IGROV1, LSD1 siRNA: G0/G1: 78.07%, S: 13.37%, G2/M: 8.56%.
T47D cells, Luc: G0/G1: 65.87%, S: 17.91%, G2/M: 16.22%; and T47D, LSD1 siRNA: G0/G1: 76.34%, S: 11.49%, G2/M: 12.17%.
H1437 cells, Luc siRNA: G0/G1: 39.53%, S: 23.30%, G2/M: 37.17%; and H1437 cells, LSD1 siRNA: G0/G1: 37.28%, S: 24.97%, G2/M: 37.75%.
See also Figure S3A.Sox2 Is the Only PSC Protein whose Expression
Correlates with Sensitivity to LSD1 Inactivation in
Carcinoma Cells
Our previous studies indicated that sensitivity to LSD1 inactiva-
tion is usually associated with cells derived from germ cell
tumors that express PSC proteins (Wang et al., 2011). Because
some breast and ovarian cancer cells in our collection were re-
ported to express PSC proteins such as Oct4, Sox2, Lin28,
Nanog, and/or Sall4 (Leis et al., 2012; Peng et al., 2010; Zhong
et al., 2010), a direct correlation between the expression of these
proteins and the sensitivity to LSD1 inactivation has not been
established. To determine the mechanism by which various car-448 Cell Reports 5, 445–457, October 31, 2013 ª2013 The Authorscinoma cells are sensitive to LSD1 inactivation, we analyzed the
expression of known PSC proteins in our collected cell lines and
correlated their expression with the sensitivity to LSD1 inactiva-
tion, using teratocarcinoma/embryonic carcinoma F9 and
NTERA-2 cells and cervical carcinoma HeLa cells as controls
(Figure 2D; Table S2) (Wang et al., 2011).
We made several notable findings using this approach. First,
we found that Oct4, Lin28, Sall4, and Nanog were each ex-
pressed in breast and ovarian carcinoma IGROV1, A2780, and
T47D cells, and all teratocarcinoma/embryonic carcinoma F9,
PA-1, and NTERA-2 cells (Figure 2D). We did not find a single
cell line that expressed these PSC proteins independently of
Figure 3. LSD1 Regulates Sox2 Expression by Modulating Bivalent H3K9 and H3K4 Methylations
(A) Inactivation of LSD1 by LSD1 inhibitors or siRNAs caused the downregulation of Sox2. The indicated carcinoma cells were treated with 50 mM of the LSD1
inhibitors CBB1007 and CBB1003 for 30 hr or with 50 nM of Luc or LSD1 siRNAs for 60 hr. The protein levels of LSD1, Sox2, Lin28, CUL1, and histone H3 were
analyzed by western blotting. See also Figure S4B.
(B) The mRNA levels of Sox2 in (A) were analyzed by real-time quantitative RT-PCR. Data are presented as mean ± SD. **p < 0.01.
(C) T47D cells were treated with 50 mM CBB1007. They were subsequently harvested at various time points as indicated. The effects of the LSD1 inhibitor on
H3K4, H3K9, and H3K27 methylations were examined.
(D) The indicated cells were transfected with 50 nM Luc or LSD1 siRNAs, and histone methylations were analyzed as in (C). See also Figures S2C, S2D, and S7F.
(E) ChIP assays for the presence of LSD1, H3K4me1/2, and H3K9me2 on the Sox2 gene in A549 cells. Chromatin-associated proteins were crosslinked to
chromatin, sonicated (average 500–1,000 bp DNA), and immunoprecipitated with control rabbit immunoglobulin G (IgG), LSD1, or H3K9me2 antibodies as
indicated. The DNA fragments were purified and used for real-time quantitative PCRwith various primers along the Sox2 promoter. Data are presented asmean ±
SD. The statistical differences for increased H3K4 and H3K9 methylations along the Sox2 gene between inhibitor-treated and control groups were analyzed by
one-way ANOVA. *p < 0.05, **p < 0.01. See also Figure S6C.
(F) Re-ChIP assays for the copresence of H3K9Me2 and H3K4Me2 on the Sox2 gene in A549 cells. Top panels: chromatin fragments were first immunopre-
cipitated with H3K9me2 antibodies or control IgG. The fragments were eluted with H3K9me2 peptide and reimmunoprecipitated with H3K4me2 antibodies.
Bottom panels: the chromatin fragments were first immunoprecipitated with H3K4me2 and then H3K9me2 antibodies. Real-time quantitative PCR ratios reflect
the relative enrichment to the input of the indicated histone methylations on Sox2 after sequential immunoprecipitations. Data are presented as the mean ± SD of
at least two independent assays.
(G) Effects of LSD1 inactivation as in (D) on the protein levels of c-Myc and cyclins.
See also Table S3.Sox2, suggesting the importance of Sox2. Second, Sox2was the
only PSC protein that was expressed alone and independently of
other PSC proteins in SKOV-3, OVCAR-3, MCF-7, MDA-MB-C361, MDA-MB-468, MDA-MB-453, NCI-H520, and A549 cells,
again indicating that Sox2 is unique for these carcinoma cells.
Third, and most importantly, our analyses revealed that allell Reports 5, 445–457, October 31, 2013 ª2013 The Authors 449
Sox2-expressing carcinoma cells were sensitive to LSD1 inacti-
vation, whereas all Sox2-negative cancer cells were insensitive
(Figure 2D; Table S2). Consistently, we also found that K562, a
human myelogenous leukemia cell, and G401, a human rhab-
doid-tumor-derived cell, also expressed Sox2, and both were
sensitive to LSD1 inhibition, whereas MDA-MB-435S, a mela-
noma cell that does not express Sox2, was insensitive (Figures
2D, S2E, and S2F; Table S2). Whereas K652 cells only express
Sox2, G401 cells also express Lin28 and Sall4. Our studies
thus indicate that there is a strong correlation between Sox2
expression and sensitivity to LSD1 inactivation.
LSD1 Inactivation of LSD1 Suppresses Sox2 Expression
and Increases theMono- andDimethylation of H3K9 and
Trimethylation of H3K27 Only in Sox2-Expressing
Carcinoma Cells
Analysis of the effects of LSD1 inactivation revealed that LSD1
inactivation consistently reduced the expression of Sox2 in
H520, A2780, T47D (Figures 3A and 3B), and other Sox2-ex-
pressing cancer cells (Figure S4B). In contrast, LSD1 inactivation
did not change the levels of Lin28, another PSC protein, which is
often coexpressed with Sox2 in a fraction of carcinoma cells
(Figures 2D, 3A, and S4B). Our results suggest that LSD1 is
required for the expression of Sox2 in these carcinoma cells.
As LSD1 is a histone demethylase that removes themono- and
dimethyl groups from methylated H3K4 (H3K4me1/me2)(Shi
et al., 2004), we found that LSD1 inactivation caused a dose-
dependent increase of H3K4me1/me2 in both Sox2-postive
and -negative cells (Figures 3C, 3D, S2C, and S2D), indicating
that the inhibitors specifically blocked LSD1 demethylase activ-
ity in all cancer cells.
Because LSD1 interacts with the androgen receptor to act as
an H3K9-specific demethylase to remove the mono- and
dimethyl groups from methylated H3K9 (H3K9me1/me2) in
certain prostate cancer cells (Metzger et al., 2005), we also
examined whether LSD1 inactivation affected H3K9me1/me2
as well as the trimethylation of histone H3 at lysine 27
(H3K27me3), which is not a target of LSD1. Strikingly, we found
that LSD1 inactivation induced global increases of both
H3K9me1/me2 and H3K27me3 only in Sox2-expressing carci-
noma cells, but not in Sox2-negative cancer cells such as
H1299 or H1437 (Figures 3C and 3D). A kinetic analysis of induc-
tion revealed that the increases of both H3K4me1/2 and
H3K9me1/2 occurred early (<1 hr) and simultaneously, whereas
H3K27me3 was induced much later (4–8 hr; Figure 3C) after
LSD1 inhibition, suggesting that the increases of H3K4me1/2-
and H3K9me1/2 are likely a direct consequence of LSD1 inhibi-
tion, and H3K27me3 elevation may occur as a secondary event.
LSD1 Binds Directly to the Transcriptional Regulatory
Region of Sox2 to Regulate Bivalent H3K4 and H3K9
Methylation
Because LSD1 inactivation reduced Sox2 expression, we tried to
determine whether Sox2 is a direct target of LSD1 by using a
chromatin immunoprecipitation (ChIP) assay (Whyte et al.,
2012) to determine whether LSD1 binds to the Sox2 gene. Our
ChIP analysis revealed that LSD1 is enriched in the transcrip-
tional regulatory region (3.0 to 4.0 kb) of the Sox2 gene (Fig-450 Cell Reports 5, 445–457, October 31, 2013 ª2013 The Authorsure 3E), a region that was reported to act as a distal enhancer for
Sox2 expression in breast cancer cells (Leis et al., 2012). This
enrichment of LSD1 appears to be specific for Sox2, as no
enrichment was observed on Lin28, Klf4, or the pericentromeric
heterochromatin region (Dovey et al., 2010; Figures 7G and
S6D), which are not regulated by LSD1.
To determine whether LSD1 binding is associated with the
demethylase activity on Sox2, we examined the presence and
changes of the characteristic H3K4me1/me2 and H3K9me1/
me2 on Sox2 after LSD1 inactivation. Repeated ChIP analyses
in Sox2-expressng cells, such as A2780 and A549 cells, consis-
tently revealed that H3K9me2 (we did not have good ChIP-
grade H3K9me1 antibodies) and H3K4me1/me2 were present
in the Sox2 regulatory region, and inhibition of LSD1 caused
significantly increased levels of both H3K9me2 and H3K4m1/
me2 on Sox2 (Figure 3E). Reciprocal re-ChIP of H3K9me2
or H3K4me2-enriched chromatin fragments revealed that
H3K9me2 and H3K4me2 coexisted on the same Sox2 regulatory
fragment (Figure 3F). Although H3K27me3 was also induced on
Sox2, themajor site was located farther down the genewithin the
coding region (+2.0; Figure S6C). Thus, our results indicate that
the Sox2 regulatory region is regulated directly by the bivalent
H3K4 and H3K9 methylations by LSD1 demethylase. Sox2
downregulation after LSD1 inactivation is likely to be directly
caused by increased repressive H3K9 methylations on the
Sox2 gene, even though H3K4me1/2 also increased on Sox2
(see below).
Our ChIP analysis also indicated that LSD1 also binds to
the cyclin A, cyclin B, and cyclin D1 genes, and inactivation
of LSD1 caused the increased levels of H3K4me1/me2,
H3K9me2, and H3K27me3 on the cyclin promoters (Figures
7F, S3B, and S6C). Thus, increased levels of H3K9me2 on the
cyclin genes may also repress the expression of cyclins, which
may contribute to the G1 cell-cycle arrest after LSD1 inactivation
(Figures 2E, 3G, S3A, and S3B).
Loss of Sox2 Phenocopies the Growth-Inhibitory Effects
of LSD1 Inactivation on Carcinoma Cells
Although Sox2 acts as an amplified lineage-survival oncogene in
lung SCCs (Bass et al., 2009), the role of Sox2 in other carcinoma
cells remains largely uncharacterized. Because LSD1 inactiva-
tion reduced Sox2 expression, we further investigated the role
of Sox2 in regulating cancer cell growth. Ablation of Sox2
expression using specific siRNAs consistently showed that it
caused G1 cell-cycle arrest and growth inhibition in Sox2-ex-
pressing carcinoma cells that are sensitive to LSD1 inactivation,
but not in Sox2-negative cancer cells (Figures 4A, 4B, 4E, S4A,
and S4C). Loss of Sox2 also downregulated c-Myc and cyclin
A, cyclin B, and cyclin D1, and induced the expression of genes
for differentiation, including FOXA2, HNF4A, BMP2, EOMES,
and Sox17 (Figures 4C and 4D). However, loss of Sox2 increased
only the levels of trimethylated H3K27, and not those of H3K4
and H3K9 methylations, suggesting that induction of H3K27 tri-
methylation after LSD1 inactivation might be an indirect conse-
quence of Sox2 downregulation (Figures 3C, 3D, and 4C). ChIP
analysis revealed that Sox2 inactivation induced elevated
H3K27me3 on Sox2 and cyclin promoters after Sox2 ablation
(Figure 4F), suggesting that increased H3K27me3 on these
Figure 4. Inactivation of Sox2CausesG1Cell-Cycle Arrest, Inhibits the Cell Growth of Sox2-Expressing CarcinomaCells, and InducesGenes
for Differentiation
(A) A549, NCI-H1437, T47D, and IGROV1 cells were transfected with 50 nM luciferase or Sox2 siRNAs for 60 hr and the cell growth of control and Sox2-ablated
cells was examined by microscopy. See also Figure S4C.
(legend continued on next page)
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genes suppressed their expression. Thus, our data indicate that
Sox2 serves as a primary and key direct target of LSD1 inactiva-
tion for growth inhibition and differentiation, because downregu-
lation of Sox2 further amplifies and enhances the effects of LSD1
inactivation through the increased levels of H3K27me3. Our
observation is consistent with previous reports of critical thresh-
olds and phenotypes associated with haploid insufficiency and
hypomorphic mutations of Sox2 in animals and human diseases
(Episkopou, 2005). Mutations of human Sox2 that compromise
one allele of the Sox2 genes were shown to cause anophthal-
mia-esophageal-genital (AEG) syndrome and exhibited neuro-
logical phenotypes, including seizures (Fantes et al., 2003;
Williamson et al., 2006), whereas hypomorphic deletion of the
enhancer of the mouse Sox2 genes, which reduced Sox2
mRNA and protein levels by 20%–30% compared with wild-
type levels, exhibited lower birth frequency and neurological
phenotypes in the mouse (Ferri et al., 2004).
Sox2 Is Involved in Mediating the Growth-Inhibitory
Effects of LSD1 Inactivation
To further determine whether reduced expression of Sox2 is
responsible for the growth inhibition caused by LSD1 inactiva-
tion, we tried to ectopically express Sox2 in Sox2-expressing
carcinoma cells. In both Sox2-expressing ovarian A2780 and
lung A549 carcinoma cells, stable and ectopic expression of
Sox2 led to a significant resistance of these cells to LSD1 inhibi-
tion as compared with control cells (Figure 5A). Coinactivation of
Sox2 and LSD1 in Sox2-expressing cancer cells by siRNAs or
LSD1 inhibitors also did not reveal any additive or synergetic
effects on growth inhibition induced by the loss of LSD1 or
Sox2 alone (Figures 5D and 5E), suggesting that LSD1 and
Sox2 act in the same pathway to control cell growth.
LSD1 was shown to interact with several proteins, such as
CoREST, in various cells (Shi et al., 2005). To confirm that
the effects of LSD1 inactivation are mediated through its
interaction with cellular proteins, we also ablated the expres-
sion of CoREST. We found that loss of CoREST caused the
same selective growth-inhibitory effects and induction of
H3K4, H3K9, and H3K27 methylations on Sox2-expressing
cancer cells, but not Sox2-negative cancer cells, as LSD1 inac-
tivation (Figure S7). It is likely that LSD1 acts through the
CoREST complex to selectively regulate the growth of Sox2-
expressing cancer cells, although loss of CoREST slightly
reduced the level of LSD1 protein, possibly because of their
in vivo association.(B) Cell cycles after Sox2 inactivation were analyzed by FACS. The cell-cycle dis
A549 cells, Luc siRNA: G0/G1: 54.68%, S: 30.52%, G2/M: 14.80%; and A549, S
H1437 cells, Luc siRNA: G0/G1: 39.69%, S: 23.11%, G2/M: 37.20%; and H1437
IGROV1 cells, Luc siRNA: G0/G1: 57.29%, S: 27.32%, G2/M: 15.39%; IGROV1,
T47D cells, Luc: G0/G1: 66.02%, S: 17.27%, G2/M: 16.71%, T47D, Sox2 siRNA
(C) The effects of Sox2 inactivation as in (B) on c-Myc, cyclins, and methylated H
(D) Induction of differentiation genes FOXA2, HNF4A, BMP2, EOMES, and Sox17
blotting and real-time quantitative RT-PCR.
(E) The indicated lung, breast, ovarian, and other carcinoma cells were transfected
by MTT assay. *p < 0.05, **p < 0.01.
(F) ChIP arrays on A549 cells with or without Sox2 siRNA-mediated ablation as in
genes.
See also Table S3.
452 Cell Reports 5, 445–457, October 31, 2013 ª2013 The AuthorsBecause Sox2-expressing carcinoma cells may be heteroge-
neous in Sox2 expression and different cells may vary in
their responses to LSD1 inactivation, we examined the clonal
response of Sox2-expressing carcinoma cells. To isolate
single cells, we used serial dilution to separate A549 cells.
Each isolated single cell was clonally expanded and character-
ized. We found that the isolated single-cell clones exhibited
different growth rates represented by their differences in colony
size (Figure 5B). Examination of Sox2 expression in various
clones revealed that smaller clones usually contained much
higher levels of Sox2 expression than the larger clones (Fig-
ure 5B). Notably, the smaller clones also expressed more
LSD1 and were more sensitive to LSD1 inhibitors than the
larger clones that expressed less Sox2 and LSD1 (Figures 5B
and 5C). These studies again underscore the correlation
between Sox2 and LSD1 expression, and indicate that cancer
cells that express higher levels of Sox2 are more sensitive to
LSD1 inhibition.
Loss of LSD1 Suppresses Sox2-Dependent, Lineage-
Specific Gene Expression and Reduces Sox2-Mediated
Repression of Genes for Differentiation
In lung SCCs, Sox2 acts as a lineage-survival oncogene that is
required for the expression of lineage-specific genes such as
TP63 and KRT6A (Bass et al., 2009). Our studies revealed that
loss of either LSD1 or Sox2 led to the downregulation of TP63
and KRT6A expression in Sox2-expressing H520 and A549,
but not in Sox2-negative H1299 lung carcinoma cells (Figures
6A and 6B). We further used ChIP assays to determine whether
LSD1 inactivation affects the ability of Sox2 to bind the pro-
moters of TP63 and KRT6A. In H520 cells, we found that Sox2
bound directly to the promoters of TP63 and KRT6A genes (Fig-
ure 6C), and inhibition of LSD1 significantly reduced the binding
of Sox2 to these lineage-specific genes (Figure 6D).
Our studies also revealed that ablation of Sox2 induced the
expression of differentiation genes such as FOXA2 and Sox17
(Figure 4D). ChIP assays indicated that Sox2 bound directly
to these promoters and inactivation of LSD1 significantly
decreased Sox2 binding to these promoters (Figures 6C and
6D), suggesting that Sox2 normally acts as a repressor of these
differentiation genes. Thus, our data confirm that LSD1 inacti-
vation acts directly on a Sox2-dependent transcriptional
program to reduce the lineage-survival oncogene function of
Sox2 and to impair Sox2-mediated repression of differentiation
genes.tribution of cells was as follows:
ox2 siRNA: G0/G1: 76.40%, S: 23.41%, G2/M: 0.19%.
cells, Sox2 siRNA: G0/G1: 39.39%, S: 25.10%, G2/M: 35.51%.
Sox2 siRNA: G0/G1: 74.62%, S: 12.87%, G2/M: 12.52%.
: G0/G1: 74.65%, S: 14.48%, G2/M: 10.86%. See also Figure S4A.
3K4, H3K9, and H3K27 proteins were analyzed by western blotting.
by Sox2 deficiency in A549, H520, A2780, and T47D cells, analyzed by western
with 50 nM luciferase or Sox2 siRNAs for 48 hr and cell growth was monitored
(B) for increases of H3K27me3 on Sox2 and cyclin A, cyclin B, and cyclin D1
Figure 5. Sox2 Is a Target of LSD1 Inactivation in Sox2-Expressing Carcinoma Cells
(A) Ectopic expression of Sox2 conferred resistance to LSD1 inhibitors. Human Sox2 cDNA was tagged with Flag epitope at the amino terminus and stably
expressed in A2780 or A549 cells using the retroviral pMSCV vector. Control and Flag-Sox2-expressing cells were treated with various concentrations of
CBB1007 for 30 hr, and cell viability was assayed and compared.
(B) Sox2-expressing A549 carcinoma cells were separated by serial dilution into single cells. The single-cell clones were expanded and two representative clones
are shown. The mRNA levels of Sox2 and LSD1 in the small and large clones were analyzed by real-time quantitative RT-PCR.
(C) The responses of the single small and large clones of A549 cells in (B) to various concentrations of CBB1007 were examined.
(D and E) Sox2-expressing A549, T47D, or A2780 cells were treated with 50 mM CBB1007 for 30 hr (D) or transfected with 50 nM luciferase, LSD1, Sox2, or
LSD1+Sox2 siRNAs for 48 hr (E), and the effects on their growth were monitored and quantified.
See also Table S3.Loss of LSD1 Induces the Expression of Genes for
Differentiation by Selectively Increasing the Levels of
Methylated H3K4, but Not Methylated H3K9 or H3K27,
on the Promoters
LSD1 inactivation in germ tumor cells or ESCs induced the
expression of genes for differentiation (Wang et al., 2011). To
determine whether the function of LSD1 is preserved in Sox2-ex-
pressing carcinoma cells, we analyzed the effects of LSD1 inac-
tivation on the expression of differentiation genes. We found that
LSD1 inactivation led to the induction of differentiation genes
such as FOXA2, HNF4A, BMP2, EOMES, and Sox17 only in
Sox2-expressing cancer cells, and not in Sox2-negative cancer
cells (Figures 7A–7D and S5). Although loss of LSD1 caused G1Ccell-cycle arrest (Figures 2E and S3A), the induction of differen-
tiation genes did not appear to be the consequence of LSD1
inactivation-induced G1 cell-cycle arrest, as arresting Sox2-
expressing A549 cells in the G1/S border alone did not promote
the induction of differentiation genes or the suppression of Sox2
expression (Figure S3C).
Because LSD1 inactivation promotes the primary global
methylations of H3K4me1/2, H3K9me1/2, and H3K27me3 in
Sox2-expressing cancer cells (Figures 3C and 3D), and
increased levels of these methylations on the promoters of
Sox2 and cyclin genes (Figures 3E, 7F, S3B, and S6C), we
examined these methylations in the regulatory regions of
differentiation genes. In sharp contrast to the increased H3K4,ell Reports 5, 445–457, October 31, 2013 ª2013 The Authors 453
Figure 6. LSD1 Inactivation Impairs Sox2 Regulation of the Expression of Lineage-Specific Genes and Genes for Differentiation
(A and B) The lineage-specific genes TP63 (A) and KRT6A (B) were downregulated after inactivation of LSD1 or Sox2. Lung carcinoma NCI-H520, A549, and
H1299 cells were either treatedwith 50 mMCBB1003 for 30 hr or transfected with Luc-, LSD1-, or Sox2-specific siRNAs for 48 hr as indicated. ThemRNA levels of
TP63 and KRT6A were measured by real-time quantitative RT-PCR. Downregulation of TP63 and KRT6A occurred in Sox2-ablated H520 and A549 cells, but not
in H1299 cells. Statistical differences between experimental and control groups were analyzed by one-way ANOVA. *p < 0.05, **p < 0.01.
(C) ChIP analysis of Sox2 binding to the promoters of TP63, KRT6A, FOXA2, and Sox17 genes using control IgG and specific Sox2 antibodies in NCI-H520 cells.
*p < 0.05, **p < 0.01.
(D) The LSD1 inhibitor CBB1007 reduced Sox2 binding to TP63, KRT6A, FOXA2, and Sox17 genes in H520 cells.
See also Figures S5, S6, and Table S3.H3K9, and H3K27 methylations on the Sox2 or cyclin genes
after LSD1 inactivation, LSD1 inhibition consistently increased
the mono- and dimethylations of H3K4 in the regulatory
regions of FOXA2, BMP2, and Sox17 genes, but not the H3K9
and H3K27 methylations in Sox2-expressing carcinoma cells
(Figures 7E, S6A, and S6B). Thus, our studies reveal a
mechanism by which LSD1 inactivation suppresses the ex-
pression of Sox2 and cyclins by increased H3K9 and H3K27454 Cell Reports 5, 445–457, October 31, 2013 ª2013 The Authorsmethylations on their regulatory regions/promoters, whereas it
causes the induction of differentiation genes by selectively
elevating the levels of H3K4me1/me2 on differentiation genes,
but not methylated H3K9 and H3K27. The effects of LSD1
inhibitors on differentiation may be enhanced by Sox2 down-
regulation, which derepresses Sox2-mediated suppression of
differentiation genes and causes further cellular differentiation
(Figure 6).
Figure 7. Inactivation of LSD1 Induces the Expression of Differentiation Genes by Increased Methylation of H3K4, but not Methylated H3K9,
and Suppression of the Cyclin A Gene by Increased H3K4me1/2 and H3K9me2
(A–C) A549, NCI-H520, H1437, A2780, and T47D cells were transfected with 50 nM luciferase or LSD1 siRNAs for 48 hr or treated with 50 mM LSD1 inhibitors
CBB1003 and 1007 for 30 hr. The effects of LSD1 inactivation on the induction of FOXA2 (A) or on various differentiation genes (FOXA2, HNF4A, BMP2, EOMES,
and Sox17 [B and C]) were analyzed by western blotting (A) or real-time quantitative RT-PCR (B and C). See also Figure S5A.
(D) The indicated lung, breast, ovarian, and other carcinoma cells were treated with 50 mM CBB1003 or CBB1007 for 30 hr, and induced expression of FOXA2
mRNAs wasmonitored, quantified, and compared between control and inhibitor-treated cells using real-time quantitative RT-PCR. *p < 0.05, **p < 0.01. See also
Figure S5B.
(E–G) ChIP assays for the presence of LSD1, H3K9me2, H3K4me1, andH3K4me2 in the regulatory regions of the differentiation gene FOXA2with or without LSD1
inhibitors for 30 hr (E; see also Figures S6A–S6C) or on the cyclin A gene (F; see also Figures S3B and S6C) and the pericentromeric heterochromatin region SAT2
and BMP2 genes (G; see also Figure S6D) after LSD1 inactivation in A549 cells. Chromatin fragments were immunoprecipitated with control rabbit IgG-, LSD1-,
H3K9me2-, H3K4me1-, and H3K4me2-specific antibodies as indicated. The DNA fragments were purified and used for real-time quantitative PCR with various
primers along the FOXA2 and cyclin A genes or the SAT2 and BMP2 regions. Data are presented as mean ± SD.
See also Table S3.DISCUSSION
Although we previously found that LSD1 inactivation selectively
inhibited the growth of pluripotent ESCs and germ tumor cells
(Wang et al., 2011), the mechanism by which these cells are
selectively sensitive to LSD1 inhibitors remains unclear. In this
study, we found that tissue-specific carcinoma cells can be
divided into two groups based on their sensitivity to LSD1 inac-Ctivation. Although some sensitive carcinoma cells express Oct4,
Lin28, and/or Sall4, we found that all carcinoma cells that are
sensitive to LSD1 inactivation consistently express Sox2, often
alone and independently of other known PSC proteins (Figures
1, 2, and S1–S3; Table S2). This correlation strongly suggests
that the growth-inhibitory effects of LSD1 inhibitors are depen-
dent on Sox2, but not other PSC proteins. Our finding that
Sox2 is the sole PSC protein expressed in a wide array of lung,ell Reports 5, 445–457, October 31, 2013 ª2013 The Authors 455
breast, ovarian, and other cancer cells suggests that Sox2 is a
master regulator of the growth, differentiation, and survival of
these cancers.
LSD1 acts primarily as a histone demethylase that removes
the methyl groups from H3K4me1/me2 to suppress gene
expression (Shi et al., 2004). Only in some prostate cancer cells
can LSD1 bind to androgen receptor in a ligand-dependent way
to remove the methyl groups from H3K9me1/me2 to activate
gene expression (Metzger et al., 2005). Strikingly, we found
that LSD1 inactivation induced a global increase of both
H3K4me1/me2 and H3K9me1/me2 in Sox2-expressing cancer
cells (Figure 3), which form bivalent chromatin domains in the
regulatory regions of Sox2 and cell-cycle regulatory genes
such as cyclins to suppress their expression (Wang et al.,
2009). Although trimethylated H3K27 was also induced, it
appears that this increase is caused by Sox2 downregulation
after LSD1 inactivation, as loss of Sox2 induced an increase of
trimethylated H3K27, but not of methylated H3K4 andH3K9 (Fig-
ure 4C). However, this increase in H3K27me3 appears to be crit-
ical for the response to LSD1 inactivation, since inactivation of
Sox2 produced the same growth-inhibitory effects that resulted
from LSD1 inhibition in cancer cells (Figures 4 and S4). In
contrast, our studies revealed that LSD1 inactivation caused
increased levels of H3K4me1/me2, but not H3K9me1/2 and
H3K27me3, in the regulatory regions of differentiation genes to
induce their expression (Figures 7 and S6). Thus, our work sug-
gests a mechanism whereby LSD1 inactivation causes selective
increased methylations of H3K4 and H3K9 on the Sox2 and cell-
cycle genes, but only induces increased H3K4 methylation on
the promoters of differentiation genes, resulting in the downre-
gulation of Sox2 and cyclins and the induction of genes for differ-
entiation. The downregulation of Sox2 consequently reduces
lineage-specific oncogenic potential and further promotes
cellular differentiation. A key event of Sox2 downregulation by
LSD1 inactivation is the induction of H3K27 trimethylation, which
further reduces the expression of Sox2 and cell-cycle genes to
amplify the growth-inhibitory and differentiation-promoting
effects of LSD1 inactivation. Our studies collectively indicate
that LSD1 is a key regulator of Sox2 expression, cell-cycle pro-
gression, and cellular differentiation in ESCs and Sox2-express-
ing cancer cells, and suggest that LSD1 can serve as a specific
and selective target for treatment of Sox2-expressing cancers.
EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture
Lung, breast, ovarian, and other carcinoma cells were obtained from the
American Type Culture Collection (ATCC) or from the DTP and DCTD Tumor
Repository of the National Cancer Institute, as listed in Table S2. They were
cultured according to instructions and treated with various concentrations of
LSD1 inhibitors for 24–30 hr for cell viability or expression assays (Wang
et al., 2011). Additional procedures are described in the Supplemental Exper-
imental Procedures.
Western Blot, Immunohistochemistry, and Antibodies
Log-phase growing cancer cells were directly lysed in a buffer containing 0.5%
SDS. Proteins in the lysates were equalized and analyzed by western blotting
using specific antibodies as described previously (Wang et al., 2011). For
immunohistochemical staining, rabbit monoclonal LSD1 and Sox2 antibodies
were obtained from Cell Signaling and immunostaining was conducted as pre-456 Cell Reports 5, 445–457, October 31, 2013 ª2013 The Authorsviously described (Wang et al., 2011). Additional experimental methods are
described in Supplemental Experimental Procedures.
Small RNAi
Cells were transfected with 50 nM siRNAs using DharmaFECT reagent 1
(Dharmacon) for 48–60 hr as described previously (Wang et al., 2011). The
siRNA sequences were GGAAGAAGAUAGUGAAAAC (for human LSD1) and
CGCUCAUGAAGAAGGAUAA (for human Sox2).
ChIP Assays
ChIP assays were carried out according to published protocols (Whyte et al.,
2012). After the chromatin proteins were crosslinked with formaldehyde,
chromatin DNAwas sonicated to an average 500–1,000 bp and used for immu-
noprecipitation by specific antibodies. DNA was isolated for quantitative real-
time PCR after the crosslinking on immunoprecipitated chromatin fragments
was reversed. The real-time PCR primers used are listed in Table S3. ChIP-
grade H3K4me2 (Ab32356), H3K4me1 (Ab8895), H3K9me2 (Ab1220), and
LSD1 (Ab17721) antibodies were obtained from Abcam. Re-ChIP for co-
occupancy of methylated H3K4 and H3K9 was conducted as previously
described (Geisberg and Struhl, 2004).
Statistical Analyses
Statistical analysis was performed using GraphPad Prism v4.0 software as
previously described (Wang et al., 2011). Data are presented as mean ± SD.
One-way ANOVA was used for comparisons.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2013.09.018.
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